Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 29, 2009

FDA Grants Emergency Use Authorization to Gen-Probe's PCR Test for the H1N1 Flu

  • Gen-Probe has been granted an EUA (emergency use authorization) for the Prodesse ProFlu-ST™ to be used in CLIA high-complexity laboratories for detection of the 2009 H1N1 influenza virus. The test is aided by an algorithm that relies on seasonal influenza A/H1 and A/H3 virus results from a single sample in individuals who are diagnosed with influenza A by currently available devices.

    Under the EUA, the agency has authorized the use of ProFlu-ST only during the H1N1 flu emergency, which is currently set to expire on April 26, 2010. The test becomes the first commercially available RT-PCR diagnostic that can detect and identify the 2009 H1N1 influenza virus, according to Gen-Probe. Test results are reportedly obtained in three hours using the assay; culture-based methods can take up to weeks to produce a result, the firm adds.

    “This test complements nicely our FDA-cleared ProFlu+ Assay, which from a single sample, detects and discriminates influenza A virus, influenza B virus, and RSV (respiratory syncytial virus),” notes Andy Shrago, head of marketing for Prodesse products.

    Both the ProFlu-ST and ProFlu+ tests were obtained through the acquisition of Prodesse, completed on October 21. Prodesse had three FDA 510(k)-cleared products and two additional CE-marked products in Europe.

    Prodesse's ProFlu+ test was sanctioned by the FDA in January 2008 for the detection and discrimination of influenza A virus, influenza B virus, and RSV. Prodesse also sold assays for the clinical diagnosis of Clostridium difficile and human metapneumovirus in the U.S.


Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »